This stratification of patients is based on the presence and the degree of radiopharmaceutical uptake on somatostatin receptor scintigraphy or PET/CT examinations, with scores varying from zero (no tumor uptake) to 4 (very intense tumor uptake), which by the end reflects the level of somatostatin expression in the detected lesions. This evidence concerns the gene SST and neoplasm.